NASDAQ$SERA

Sera Prognostics Inc-A · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Briefing

Sera Prognostics Inc-A reported Q2 2025 results showing minimal revenue and continued net losses amid ongoing commercialization efforts.

For the three months ended June 30, 2025, the company recorded revenue of $17,000 and a net loss of $8.0 million. Operating expenses totaled $9.3 million, driven by research and development, selling and marketing, and general and administrative costs. Cash and cash equivalents stood at $5.0 million with total assets of $111.8 million at quarter end.

  • Revenue for Q2 2025 was $17,000, down from $24,000 in Q2 2024.
  • Net loss narrowed slightly to $8.0 million from $8.3 million year-over-year.
  • Cash position improved to $5.0 million from $4.0 million at year-end 2024 following equity offering.
  • Total assets reached $111.8 million, supported by marketable securities and recent financing.

Headline financials

Total Revenue

$17K

Previous: $24K-29.2%
EPS (adj)

-$0.16

Previous: -$0.25+36.0%
Capital Expenditures

-$284K

Previous: -$22K-1190.9%
Net Income

-$8.05M

Previous: -$8.3M+3.1%
Operating Income

-$9.32M

Previous: -$9.25M-0.7%
Cash & Equivalents

$5.02M

Previous: $4.66M+7.5%
Total Assets

$112M

Previous: $84.9M+31.8%

Revenue & EPS history

Sera Prognostics · Revenue · Quarterly

$17K

Q2 2025-29.2%vs Q2 2024
Beat estimate in 3 of 16 quarters(19%)
ActualEstimate

Forward guidance

The company expects continued operating losses while focusing on PreTRM test commercialization and pipeline development, with cash runway sufficient through 2028.

Tailwinds

  • Cash runway extended through 2028 based on current operating plans.
  • Recent equity offering provided $53.6 million in net proceeds.
  • Clinical evidence from PRIME and AVERT studies supports potential market adoption.

Headwinds

  • Ongoing net losses and limited revenue generation.
  • Dependence on third-party payers for reimbursement remains uncertain.
  • Commercial expansion requires additional investment in sales and marketing.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

-1.9%

Avg return

Earnings day

-3.5%

Avg return

5 days after

-3.3%

Avg return

30 days after

36%

8 / 22 earnings

Positive

+14.3%

Q3 2022

Best reaction

-11.7%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2026-3.7%-8.0%+18.1%
Q4 2025-7.7%+6.3%+20.4%
Q3 2025+1.7%+8.5%+19.0%
Q1 2025-11.7%-2.1%-35.4%
Q4 2024-5.1%-2.2%-17.9%
Q3 2024-0.3%-2.7%-3.9%
Q2 2024+0.0%-1.2%-2.2%
Q1 2024+3.3%-4.0%-13.6%
Q4 2023+3.4%+1.1%+7.7%
Q3 2023-3.2%-6.4%+130.9%
Q2 2023+0.8%-10.1%-39.9%
Q1 2023-0.8%-2.8%-13.0%
Q4 2022-10.0%-9.5%-22.3%
Q3 2022+14.3%+11.1%-4.0%
Q2 2022-4.1%-6.3%-27.3%
Q1 2022-7.6%-17.1%-32.7%
Q4 2021+3.6%+0.3%-39.3%
Q3 2021+0.3%-0.8%-8.2%
Q3 2020+0.3%-0.8%-8.2%
Q1 2021-4.8%-9.9%+0.0%
Q2 2021-4.8%-9.9%+0.0%
Q4 2020-4.8%-9.9%+0.0%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro